

## ELUVIA<sup>™</sup> DRUG-ELUTING STENT 2021 CODING AND REIMBURSEMENT GUIDE

# The procedure codes listed below are applicable to Femoral / Proximal Popliteal cases involving Eluvia.

Claims must contain the appropriate CPT/HCPCS/ICD-10-PCS code(s) for the specific site of service to indicate the items and services that are furnished. The tables below contain a list of possible CPT/HCPCS/ICD-10-PCS codes that may be used to bill for Eluvia. Providers should select the most appropriate code(s) and modifier(s] with the highest level of detail to describe the service(s) actually rendered.

#### **HOSPITAL OUTPATIENT**

CPT®	Abbreviated Description	APC	Payment <sup>1</sup>	MD-In Facility <sup>1</sup>
37226	Femoral/Popliteal PTA + Stent	5193	\$10,043	\$493
37227	Femoral/Popliteal PTA, Atherectomy + Stent	5194	\$16,094	\$686

C-codes are used to report devices used in combination with device-related procedures for hospital outpatient services.

- As Eluvia is a new and novel technology, Boston Scientific believes that currently available C-codes do not
  accurately describe it.
- However, the closest applicable C-code to report the use of Eluvia is C1874, defined as "Stent, coated/covered, with delivery system".

The Medicare Reimbursement values for each MS-DRG, while specific to your hospital, do not include pass-through payments or New Technology Add-On Payment (NTAP) as these are calculated on a case-by-case basis.

#### **HOSPITAL INPATIENT**

CPT <sup>®</sup>	Abbreviated Description	MS DRG <sup>4</sup>	Payment <sup>5</sup>	MD-In Facility <sup>1</sup>
37226	Femoral/Popliteal PTA + Stent	<ul><li>252</li><li>253</li><li>254</li></ul>	\$21,931 \$17,499 \$11,975	\$493
37227	Femoral/Popliteal PTA, Atherectomy + Stent			\$686

• Denotes DRG assigned to patient w/ MCC (Major Complications or Comorbidities)

• Denotes DRG assigned to patient w/ CC (Complications or Comorbidities)

Denotes DRG assigned to patient w/o MCC or CC

Hospitals may use the ICD-10-PCS codes on the next page to report the use of Eluvia. For dates of service starting October 1, 2020, IPPS-participating acute care hospitals will be eligible to receive a NTAP. See our Eluvia NTAP Guide for additional information.

CPT® Copyright 2020 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association.

See important notes on the uses and limitations of this information on page 3.

#### Eluvia

ICD-10-PCS	Description			
Right Femoral Artery:				
X27H385	Dilation, Right Femoral Artery w/ Sustained Release DES, Perc Approach			
X27H395	Dilation, Right Femoral Artery w/ 2 Sustained Release DESs, Perc Approach			
X27H3B5	Dilation, Right Femoral Artery w/ 3 Sustained Release DESs, Perc Approach			
X27H3C5	Dilation, Right Femoral Artery w/ 4 or > Sustained Release DESs, Perc Approach			
Left Femoral Artery	<i>.</i>			
X27J385	Dilation, Left Femoral Artery w/ Sustained Release DES, Perc Approach			
X27J395	Dilation, Left Femoral Artery w/ 2 Sustained Release DESs, Perc Approach			
X27J3B5	Dilation, Left Femoral Artery w/ 3 Sustained Release DESs, Perc Approach			
X27J3C5	Dilation, Left Femoral Artery w/ 4 or > Sustained Release DESs, Perc Approach			
Proximal Right Pop	Diteal Artery:			
X27K385	Dilation, Proximal Right Popliteal Artery w/ Sustained Release DES, Perc Approach			
X27K395	Dilation, Proximal Right Popliteal Artery w/ 2 Sustained Release DESs, Perc Approach			
X27K3B5	Dilation, Proximal Right Popliteal Artery w/ 3 Sustained Release DESs, Perc Approach			
X27K3C5	Dilation, Proximal Right Popliteal Artery w/ 4 or > Sustained Release DESs, Perc Approach			
Proximal Left Popli	iteal Artery:			
X27L385	Dilation, Proximal Left Popliteal Artery w/ Sustained Release DES, Perc Approach			
X27L395	Dilation, Proximal Left Popliteal Artery w/ 2 Sustained Release DESs, Perc Approach			
X27L3B5	Dilation, Proximal Left Popliteal Artery w/ 3 Sustained Release DESs, Perc Approach			
X27L3C5	Dilation, Proximal Left Popliteal Artery w/ 4 or > Sustained Release DESs, Perc Approach			

The coding options listed within this guide are commonly used codes and are not intended to be an all-inclusive list. We recommend consulting your relevant manuals for appropriate coding options.

Sources:

- 1. 2021 Physician Fee Schedule. CMS-1734-F. <u>https://www.cms.gov/medicaremedicare-fee-service-paymentphysicianfeeschedpfs-federal-regulation-notices/cms-1734-f</u> 2021 Conversion Factor of \$34.8931.
- 2. 2021 ASC Payment. CMS-1736-FC ASC. <u>https://www.cms.gov/medicaremedicare-fee-service-paymentascpaymentasc-regulations-and-notices/cms-1736-fc</u>
- 3. 2021 OPPS Payment. CMS-1736-FC. <u>https://www.cms.gov/medicaremedicare-fee-service-paymenthospitaloutpatientppshospital-outpatient-regulations-and-notices/cms-1736-fc</u>
- 4. MS-DRG V38.1. <u>https://www.cms.gov/Medicare/Medicare-Fee-for-Service-Payment/AcuteInpatientPPS/MS-DRG-Classifications-and-Software</u>
- 5. 2022 IPPS Payment. CMS-1752-F. https://public-inspection.federalregister.gov/2021-16519.pdf

See important notes on the uses and limitations of this information on page 3.

### **IMPORTANT INFORMATION**

Health economic and reimbursement information provided by Boston Scientific Corporation is gathered from third-party sources and is subject to change without notice as a result of complex and frequently changing laws, regulations, rules, and policies. This information is presented for illustrative purposes only and does not constitute reimbursement or legal advice. Boston Scientific encourages providers to submit accurate and appropriate claims for services. It is <u>always</u> the provider's <u>sole</u> responsibility to determine medical necessity, the proper site for delivery of any services, and to submit appropriate codes, charges, and modifiers for services rendered. It is also always the provider's responsibility to understand and comply with Medicare national coverage determinations (NCD), Medicare local coverage determinations (LCD), and any other coverage requirements established by relevant payers which can be updated frequently. Boston Scientific recommends that you consult with your payers, reimbursement specialists, and/or legal counsel regarding coding, coverage, and reimbursement matters.

Boston Scientific does not promote the use of its products outside its FDA-approved label. Payer policies will vary and should be verified before treatment for limitations on diagnosis, coding, or site of service requirements. All trademarks are the property of their respective owners.

This coding information may include codes for procedures for which Boston Scientific currently offers no cleared or approved products. In those instances, such codes have been included solely in the interest of providing users with comprehensive coding information and are not intended to promote the use of any Boston Scientific products for which they are not cleared or approved. The Health Care Provider (HCP) is solely responsible for selecting the site of service and treatment modalities appropriate for the patient based on medically appropriate needs of that patient and the independent medical judgment of the HCP.

CPT ® Copyright 2020 American Medical Association. All rights reserved. CPT is a registered trademark of the American Medical Association. Applicable FARS/DFARS Restrictions Apply to Government Use. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. All trademarks are the property of their respective owners.



Advancing science for life™

Peripheral Interventions One Scimed Place Maple Grove, MN 55311-1566 https://www.bostonscientific.com/reimbursement

#### Medical Professionals:

PI.Reimbursement@Bsci.com (844) 201-2203

© 2021 Boston Scientific Corporation or its affiliates. All rights reserved.

PI-577408-AE